Cyclerion Becomes Korsana Biosciences After Reverse Merger; Stock Falls 19.5%

What happened

Korsana Biosciences, Inc. — formerly Cyclerion Therapeutics, Inc. — disclosed in a Form 8-K filed September 11, 2026 that it completed a business combination with private Delaware company Korsana Biosciences, Inc. on September 8, 2026, according to the filing.

The transaction closed under an Agreement and Plan of Merger and Reorganization dated April 1, 2026, later amended April 17, 2026. Two wholly owned Cyclerion subsidiaries merged into Korsana in sequence, leaving Korsana as a wholly owned Cyclerion subsidiary named Korsana Biosciences Operating Company, LLC. Cyclerion then changed its own name to Korsana Biosciences, Inc. The company's common stock trades on the Nasdaq Capital Market; the filing lists the symbol as KRSA, while the ticker on this event record is CYCN.

The filing states that Cyclerion stockholders owned approximately 1.17% of the combined company on a fully diluted basis immediately after closing, and Korsana securityholders owned approximately 98.83%. That is the signature of a reverse merger: a private company takes over a public shell's listing rather than being bought by it.

Concurrently with the merger, Korsana raised approximately $380.0 million in gross proceeds in a pre-closing financing, selling 140,516,748 shares of Korsana common stock and 20,171,986 Korsana pre-funded warrants to institutional and accredited investors, per the filing. The price was set from a $268.4 million valuation for Korsana divided by its fully diluted share count.

The filing also reports a reverse stock split before the merger's effective time, support agreements from holders of about 43.9% of Korsana capital stock and about 24.2% of Cyclerion common stock, and lock-up agreements covering certain Korsana officers, directors and stockholders for 180 days after the First Effective Time.

Market reaction

The shares closed at $23.94 on the event date, down 19.53% from the prior close of $29.75. Volume was 62,228 shares against an average of 5,761 — about 10.8 times normal.

The price data show the move but do not explain it. The filing does not state a reason for the decline, and no source provided here attributes it to any specific cause.

What this means

A Form 8-K is the current report public companies must file with the SEC when certain specified events occur — not on a quarterly schedule, but within four business days of the trigger. The numbered items in this filing map to the events described: 2.01 for completing an acquisition or disposition of assets, 5.01 for a change in control, 5.02 for director or officer changes, 5.03 for charter or bylaw amendments, 3.02 for unregistered sales of equity, and 2.02 for results of operations. A single 8-K can carry many items when one transaction triggers all of them, as here.

A reverse merger is the mechanism by which a private company becomes publicly traded without filing for its own initial public offering. The public company — here Cyclerion — issues shares to the private company's owners until they hold nearly all of it, then renames itself. Cyclerion securityholders keep about 1.17% of the combined company; Korsana's holders take the rest. For Cyclerion shareholders, that is severe dilution, though the filing presents it as the agreed deal terms rather than a surprise.

The Exchange Ratio of 0.2074 Cyclerion shares per Korsana share, adjusted for the reverse stock split, is how the two sides' relative values were converted into ownership percentages. The merger is intended to be tax-free as a reorganization under Section 368(a) of the Internal Revenue Code, meaning shareholders generally are not meant to owe tax on the exchange of shares itself.

Pre-funded warrants are a financing instrument that behaves like stock but is technically an option. Buyers pay almost the full share price up front and hold a warrant to buy the share later for $0.0001 — effectively a formality — often because ownership limits or regulatory approvals prevent them from holding common shares outright. They do not expire, carry no voting or dividend rights until exercised, and cannot be exercised if doing so would push the holder past a stated ownership cap such as 4.99%, 9.99% or 14.99%, which can be raised on notice if the holder wants more.

Lock-up agreements bar insiders from selling shares for a set period, here 180 days after the First Effective Time, with carve-outs for shares bought in the financing. They exist in part so that newly public stock is not immediately swamped by insider selling.

Cyclerion's options and restricted stock awards were accelerated before closing; options with exercise prices at or below a five-day average closing price were cashed out at the spread and options above it were cancelled for nothing. The filing states the company's business classification as pharmaceutical preparations, but otherwise does not describe what the combined company intends to develop or when it will report financial results.